FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2502300957> ?p ?o ?g. }

• W2502300957 endingPage "404" @default.
• W2502300957 startingPage "397" @default.
• W2502300957 abstract "In the present study, an open-label, three-treatment, three-period clinical study of rosuvastatin (RSV) and rifampicin (RIF) when administered alone and in combination was conducted in 12 male healthy subjects to determine if coproporphyrin I (CP-I) and coproporphyrin III (CP-III) could serve as clinical biomarkers for organic anion transporting polypeptide 1B1 (OATP1B1) and 1B3 that belong to the solute carrier organic anion gene subfamily. Genotyping of the human OATP1B1 gene was performed in all 12 subjects and confirmed absence of OATP1B1*5 and OATP1B1*15 mutations. Average plasma concentrations of CP-I and CP-III prior to drug administration were 0.91 ± 0.21 and 0.15 ± 0.04 nM, respectively, with minimum fluctuation over the three periods. CP-I was passively eliminated, whereas CP-III was actively secreted from urine. Administration of RSV caused no significant changes in the plasma and urinary profiles of CP-I and CP-III. RIF markedly increased the maximum plasma concentration (Cmax) of CP-I and CP-III by 5.7- and 5.4-fold (RIF) or 5.7- and 6.5-fold (RIF+RSV), respectively, as compared with the predose values. The area under the plasma concentration curves from time 0 to 24 h (AUC0-24h) of CP-I and CP-III with RIF and RSV increased by 4.0- and 3.3-fold, respectively, when compared with RSV alone. In agreement with this finding, Cmax and AUC0-24h of RSV increased by 13.2- and 5.0-fold, respectively, when RIF was coadministered. Collectively, we conclude that CP-I and CP-III in plasma and urine can be appropriate endogenous biomarkers specifically and reliably reflecting OATP inhibition, and thus the measurement of these molecules can serve as a useful tool to assess OATP drug-drug interaction liabilities in early clinical studies." @default.
• W2502300957 created "2016-08-23" @default.
• W2502300957 creator A5009966491 @default.
• W2502300957 creator A5010800795 @default.
• W2502300957 creator A5011240907 @default.
• W2502300957 creator A5012096877 @default.
• W2502300957 creator A5026533747 @default.
• W2502300957 creator A5031797992 @default.
• W2502300957 creator A5032674117 @default.
• W2502300957 creator A5035465180 @default.
• W2502300957 creator A5054708440 @default.
• W2502300957 creator A5058112913 @default.
• W2502300957 creator A5066879428 @default.
• W2502300957 creator A5085761763 @default.
• W2502300957 creator A5087048002 @default.
• W2502300957 creator A5089764461 @default.
• W2502300957 creator A5091849244 @default.
• W2502300957 date "2016-06-17" @default.
• W2502300957 modified "2023-10-11" @default.
• W2502300957 title "Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition" @default.
• W2502300957 cites W1783939843 @default.
• W2502300957 cites W1868407335 @default.
• W2502300957 cites W1894357711 @default.
• W2502300957 cites W1906327586 @default.
• W2502300957 cites W1980290263 @default.
• W2502300957 cites W1983184704 @default.
• W2502300957 cites W1985330287 @default.
• W2502300957 cites W1985480034 @default.
• W2502300957 cites W1989248448 @default.
• W2502300957 cites W2000484916 @default.
• W2502300957 cites W2003455288 @default.
• W2502300957 cites W2005998697 @default.
• W2502300957 cites W2014565106 @default.
• W2502300957 cites W2017964634 @default.
• W2502300957 cites W2024981560 @default.
• W2502300957 cites W2029727742 @default.
• W2502300957 cites W2036888384 @default.
• W2502300957 cites W2046057128 @default.
• W2502300957 cites W2046867745 @default.
• W2502300957 cites W2047718984 @default.
• W2502300957 cites W2051009834 @default.
• W2502300957 cites W2062240181 @default.
• W2502300957 cites W2063350956 @default.
• W2502300957 cites W2064188805 @default.
• W2502300957 cites W2076222174 @default.
• W2502300957 cites W2079222907 @default.
• W2502300957 cites W2081656085 @default.
• W2502300957 cites W2101501447 @default.
• W2502300957 cites W2102417187 @default.
• W2502300957 cites W2105813268 @default.
• W2502300957 cites W2107282368 @default.
• W2502300957 cites W2113719939 @default.
• W2502300957 cites W2118801143 @default.
• W2502300957 cites W2120356978 @default.
• W2502300957 cites W2131983256 @default.
• W2502300957 cites W2139121124 @default.
• W2502300957 cites W2142173547 @default.
• W2502300957 cites W2153118465 @default.
• W2502300957 cites W2156233568 @default.
• W2502300957 cites W2156466311 @default.
• W2502300957 cites W2172273796 @default.
• W2502300957 cites W2187856620 @default.
• W2502300957 cites W2337728755 @default.
• W2502300957 cites W2400987682 @default.
• W2502300957 doi "https://doi.org/10.1124/jpet.116.234914" @default.
• W2502300957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27317801" @default.
• W2502300957 hasPublicationYear "2016" @default.
• W2502300957 type Work @default.
• W2502300957 sameAs 2502300957 @default.
• W2502300957 citedByCount "124" @default.
• W2502300957 countsByYear W25023009572016 @default.
• W2502300957 countsByYear W25023009572017 @default.
• W2502300957 countsByYear W25023009572018 @default.
• W2502300957 countsByYear W25023009572019 @default.
• W2502300957 countsByYear W25023009572020 @default.
• W2502300957 countsByYear W25023009572021 @default.
• W2502300957 countsByYear W25023009572022 @default.
• W2502300957 countsByYear W25023009572023 @default.
• W2502300957 crossrefType "journal-article" @default.
• W2502300957 hasAuthorship W2502300957A5009966491 @default.
• W2502300957 hasAuthorship W2502300957A5010800795 @default.
• W2502300957 hasAuthorship W2502300957A5011240907 @default.
• W2502300957 hasAuthorship W2502300957A5012096877 @default.
• W2502300957 hasAuthorship W2502300957A5026533747 @default.
• W2502300957 hasAuthorship W2502300957A5031797992 @default.
• W2502300957 hasAuthorship W2502300957A5032674117 @default.
• W2502300957 hasAuthorship W2502300957A5035465180 @default.
• W2502300957 hasAuthorship W2502300957A5054708440 @default.
• W2502300957 hasAuthorship W2502300957A5058112913 @default.
• W2502300957 hasAuthorship W2502300957A5066879428 @default.
• W2502300957 hasAuthorship W2502300957A5085761763 @default.
• W2502300957 hasAuthorship W2502300957A5087048002 @default.
• W2502300957 hasAuthorship W2502300957A5089764461 @default.
• W2502300957 hasAuthorship W2502300957A5091849244 @default.
• W2502300957 hasBestOaLocation W25023009571 @default.
• W2502300957 hasConcept C104317684 @default.
• W2502300957 hasConcept C112705442 @default.
• W2502300957 hasConcept C135763542 @default.

• next